-- Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.
The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.
Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.